GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (NYSE:NVS) » Definitions » Loans Receivable

Novartis AG (Novartis AG) Loans Receivable

: $0 Mil (As of Dec. 2023)
View and export this data going back to 1996. Start your Free Trial

Novartis AG's Loans Receivable for the quarter that ended in Dec. 2023 was $0 Mil.


Novartis AG Loans Receivable Historical Data

The historical data trend for Novartis AG's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Novartis AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Loans Receivable Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Novartis AG Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Novartis AG Loans Receivable Related Terms

Thank you for viewing the detailed overview of Novartis AG's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (Novartis AG) Business Description

Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.